News

PipelineReview.com14h
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
Title: ATYR0101: A New Approach to Fibrosis Presenter: Ryan Adams, Ph.D., Senior Director, In Vitro Biology Session: Showcase Three: ILD/Fibrosis Date and Time: Saturday, May 17, 2025 at 11:30 AM PT ...
PipelineReview.com14h
Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
SOUTH SAN FFRANCISCO, CA, USA and BAGSVAERD, Denmark I May 14, 2025 I Septerna, Inc. (Nasdaq: SEPN) and Novo Nordisk today announced an exclusive global ...
PipelineReview.com14h
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
PARAMUS, NJ, USA I May 14, 2025 I NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced today that the U.S. Food ...
PipelineReview.com14h
Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics
SEONGNAM, South Korea I May 15, 2025 I Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today ...
PipelineReview.com15h
Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data
MENLO PARK, CA, USA I May 14, 2025 I Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company developing novel immunomodulatory therapeutics ...
PipelineReview.com3d
REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
ROCKVILLE, MD, USA I May 13, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the ...
PipelineReview.com3d
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 – – On track to initiate similarly-designed Phase 2 study in patients with COPD imminently S ...
PipelineReview.com4d
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
WALTHAM, MA, USA I May 12, 2025 I Invivyd, Inc. (Nasdaq: IVVD) today announced it has initiated a discovery program for a measles monoclonal antibody (mAb). Multiple healthcare providers (HCPs) who ...
PipelineReview.com4d
Leucid Bio Announces Treatment of First Patient in AERIAL Trial of NKG2D CAR-T Therapy LEU011 for Solid Tumours
LONDON, UK I May 12, 2025 I Leucid Bio (“Leucid” or “The Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies ...
PipelineReview.com4d
CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy
SHANGHAI, China I May 11, 2025 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces preliminary clinical data for ...
PipelineReview.com4d
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF
The RENEW Phase 2 trial will enroll up to 120 IPF patients with topline data expected in the first half of 2026 In the previously reported Phase 1b study, LTI-03 showed a positive trend in seven out ...
PipelineReview.com4d
Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers
NEW YORK, NY, USA I May 12, 2025 I Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company developing innovative therapies for unmet medical needs, today announced ...